DORMANT studio
localhost:3000

Opportunity radar

4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05

Showing50 of 30,058
Free-text
CPC starts with (comma sep)
Min fwd citations
Clear
Patent #TitleAssetsIssuedExpiresFwd citesScore
12599634Nerve guidance conduit comprising neural crest stem-like cells and/or Schwann cell precursor-like cells and methods of making and using the same🖼🧊📄§2026-04-142042-09-22031
12599661Immunogenic compositions of hepatitis c virus and uses thereof🖼🧊📄§2026-04-142042-12-12031
12599600Compositions and methods for preventing and treating headache through enhancing 2-arachydonyl glyerol activity🖼🧊📄§2026-04-142041-05-26031
12600716Compounds for modulating activity of FXR and uses thereof🖼🧊📄§2026-04-142040-10-12031
12600755Cobra 1/NELF-B as a booster for efficacy of CD8+ T cell-based therapy🖼🧊📄§2026-04-142041-02-25031
12600715Soluble guanylate cyclate activators for treating systemic sclerosis🖼🧊📄§2026-04-142043-11-02031
12599601Antifungal composition containing carbazole compound as active ingredient🖼🧊📄§2026-04-142040-10-16031
12599579Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids🖼🧊📄§2026-04-142045-07-07031
12599606Therapies with 3rd generation EGFR tyrosine kinase inhibitors🖼🧊📄§2026-04-142043-08-22031
12599603Methods of treatment🖼🧊📄§2026-04-142040-09-03031
12599617Methods of treating head and neck cancers with hemp extract🖼🧊📄§2026-04-142042-10-26031
12599571Method for preparing polydopamine nanomotor using urease, and use of same🖼🧊📄§2026-04-142040-03-10031
12599658Hepatitis B virus-specific T cell responses🖼🧊📄§2026-04-142040-06-05031
12600771Antibody for binding to interleukin 4 receptor🖼🧊📄§2026-04-142043-11-15031
12599602Methods for treating cholestasis🖼🧊📄§2026-04-142044-01-25031
12600729New-type benzazepine fused ring derivative🖼🧊📄§2026-04-142042-03-04031
12600725Selective GRP94 inhibitors and uses thereof🖼🧊📄§2026-04-142042-01-21031
12599635Compositions and treatments for ischemic injuries🖼🧊📄§2026-04-142041-03-22031
12600750Methods for inactivating and storing respiratory syncytial virus🖼🧊📄§2026-04-142039-07-08031
12600733KRAS inhibitors🖼🧊📄§2026-04-142045-09-30031
12600959PH20 polypeptide variants, formulations and uses thereof🖼🧊📄§2026-04-142045-03-05031
12600767Compounds and methods targeting epiregulin🖼🧊📄§2026-04-142042-05-19031
12600778Rage antibodies, fragments and uses thereof🖼🧊📄§2026-04-142040-11-02031
12600711Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors🖼🧊📄§2026-04-142042-05-11031
12600782Anti-PD-L1 and PD-L2 antibody and derivatives and use thereof🖼🧊📄§2026-04-142041-03-30031
12600796Constructs for chimeric antigen receptors🖼🧊📄§2026-04-142041-09-16031
12600968Methods and compositions for reprogramming cells🖼🧊📄§2026-04-142042-07-20031
12600760Chimeric antigen receptors targeting CD79B and CD19🖼🧊📄§2026-04-142039-12-13031
12600797Fibrin-binding antibody and pharmaceutical composition containing antibody🖼🧊📄§2026-04-142041-03-30031
12600772Therapeutic agent for asthma containing IL-6 inhibitor🖼🧊📄§2026-04-142039-01-31031
12600765Target for anti-cancer and immune-enhancing🖼🧊📄§2026-04-142041-04-09031
12600781Tumor-targeted agonistic CD28 antigen binding molecules🖼🧊📄§2026-04-142042-11-17031
12600785Method of screening for compounds that inhibit proliferation of pancreatic cancer cells having a loss-of-function mutation in the RNF43 gene🖼🧊📄§2026-04-142041-02-15031
12600784Anti-Clec12A antibodies and uses thereof🖼🧊📄§2026-04-142042-04-25031
12600787Methods for the treatment of thyroid eye disease🖼🧊📄§2026-04-142042-03-10031
12600788Compositions and methods for treatment of thyroid eye disease🖼🧊📄§2026-04-142045-06-18031
12600758Interleukin-2 muteins for the expansion of T-regulatory cells🖼🧊📄§2026-04-142040-08-13031
12600713Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide🖼🧊📄§2026-04-142044-02-27031
12600709Nonpeptide somatostatin type 5 receptor agonists and uses thereof🖼🧊📄§2026-04-142044-09-03031
12600722Tetracyclic compounds as DGK inhibitors🖼🧊📄§2026-04-142043-07-17031
12600730Substituted cyclopenta[c]pyrroles as ABHD6 antagonists🖼🧊📄§2026-04-142044-04-08031
12600728Interleukin-17 inhibitors🖼🧊📄§2026-04-142041-11-01031
12600727Treatment of infections of toxoplasma gondii and closely related parasites🖼🧊📄§2026-04-142039-09-18031
12599323Methods and systems for treating pregnancy-related hypertensive disorders comprising anti-sEng and anti-sFlt-1 antibodies🖼🧊📄§2026-04-142040-12-08031
12600717Tricyclic compounds as inhibitors of KRAS🖼🧊📄§2026-04-142042-07-13031
12600775Chimeric antigen receptor T cell therapy🖼🧊📄§2026-04-142040-11-06031
12600756Recombinant modified fibroblast growth factors and therapeutic uses thereof🖼🧊📄§2026-04-142042-09-07031
12599605Uric acid liposomes🖼🧊📄§2026-04-142042-10-25031
12599589Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome🖼🧊📄§2026-04-142040-12-24031
12599153Compositions and methods for reducing greenhouse gas🖼🧊📄§2026-04-142043-03-23031